Tdcs And cogNitive traininG cOmbined for AUD (TANGO)
Launched by UNIVERSITY OF MINNESOTA · Sep 21, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The TANGO trial is researching a new way to help people with Alcohol Use Disorder (AUD) by combining two techniques: a type of brain stimulation called transcranial direct current stimulation (tDCS) and cognitive training exercises. The goal is to see if this combination can help improve decision-making skills and support long-term recovery from alcohol use. By understanding how individual differences, like genetics, affect treatment responses, the researchers hope to find better ways to help people stay sober and reduce the chance of relapse.
To participate in this study, you need to meet specific criteria. You should have a diagnosis of AUD, be currently abstinent from alcohol, and be committed to staying in the program until the study is completed. However, certain health conditions, such as a history of severe head injuries or neurological issues, may prevent you from joining. If you decide to participate, you can expect to receive both the brain stimulation and cognitive training as part of the program, which aims to help you manage your recovery more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meet the Diagnostic and Statistical Manual of Mental Disorders diagnostic criteria for AUD
- • Abstinent from alcohol use
- • Must have the intention to remain in the Lodging Plus program until the end of the intervention portion of the study.
- Exclusion Criteria:
- • Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness\>30 min, HIV)
- • A head injury resulting in a skull fracture or a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
- • Any contraindications for tDCS or MRI scanning (tDCS contraindication: history of seizures; MRI contraindications; metal implants, pacemakers or any other implanted electrical device, injury with metal, braces, dental implants, non-removable body piercings, pregnancy, breathing or moving disorder)
- • Any primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder); Participants with other treated and stable psychiatric disorders will be included
- • Presence of a condition that would render study measures difficult or impossible to administer or interpret
- • Primary current substance use disorder diagnosis on a substance other than alcohol except for caffeine or nicotine
- • Clinical evidence for Wernicke-Korsakoff syndrome
- • Left-handedness
- • Entrance to the treatment program under a court mandate
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Jazmin Camchong, PhD
Principal Investigator
Univeristy of Minnesota Department of Psychiatry & Behavioral Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials